BiotechTube

Nanatinostat in combination with valganciclovir

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epstein-Barr Virus Associated Lymphoma

Conditions

Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD, EBV-Related Lymphoproliferative Disorder

Trial Timeline

May 28, 2021 → Jan 31, 2025

NCT ID
NCT05011058

About Nanatinostat in combination with valganciclovir

Nanatinostat in combination with valganciclovir is a phase 2 stage product being developed by Viracta Therapeutics for Epstein-Barr Virus Associated Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05011058. Target conditions include Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma.

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05011058Phase 2Terminated

Competing Products

5 competing products in Epstein-Barr Virus Associated Lymphoma

See all competitors
ProductCompanyStageHype Score
mRNA-1189ModernaPhase 1
0
mRNA-1189ModernaPhase 2
0
mRNA-1195.1ModernaPhase 1
0
Durvalumab + EpacadostatAstraZenecaPhase 2
27
tabelecleucelAtara BiotherapeuticsPre-clinical
16